NCT07527325 2026-04-14Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanomaUniversity of California, IrvinePhase 2 Not yet recruiting35 enrolled
NCT07511036 2026-04-06PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable MelanomaM.D. Anderson Cancer CenterPhase 2 Not yet recruiting20 enrolled